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Endovascular treatment for abdominal aortic
aneurysms (AAAs) is now a widely accepted and avail-
able option for many patients.1-3 Significant evolution
of technology regarding this relatively new method of
treatment has occurred over the past several years.2-4
Currently, there are two Food and Drug Admini-
stration (FDA) approved devices on the market:
Ancure (Guidant-Endovascular Technologies, Menlo
Park, Calif) and AneuRx (Medtronic, Minneapolis,
Minn). It is anticipated that at least two or three new
devices will be approved within the next 2 years. 
As expected with any new form of treatment,
long-term or even midterm results have not yet been
clearly defined.5,6 Most available reports have
detailed the early perioperative results or follow-up
for up to 1 year. Of particular importance is that the
definition of successful treatment has been a moving
target. Technical implantation success was first
reported; success was later modified to include the
absence of endoleaks, and most recently the avoid-
ance of rupture. The simple lack of increase in AAA
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Purpose: Shrinkage of an abdominal aortic aneurysm (AAA) is the hallmark of success-
ful endoluminal treatment. Our goal was to prospectively assess the midterm to long-
term shrinkage of the AAA sac after endovascular repair. 
Methods: A total of 123 patients with AAA underwent endoluminal treatment with the
Ancure device at our institution between February 1996 and February 2000. At least a
1-year follow-up was available for 70 of the 123 patients. AAA sac size, presence of
endoleaks, calcifications, and outcome data were collected on these patients at 6, 12, 24,
and 36 months after repair and compared with the preoperative AAA size and charac-
teristics. All endoleaks found at the 6-month follow-up visit were treated aggressively
with embolotherapy. An AAA sac regression of 0.5 cm or more was considered the min-
imum measurable decrease. Regression of the sac diameter to 3.5 cm or less was consid-
ered a complete collapse of the sac.
Results: Successful endoluminal repair was accomplished in 119 of 123 patients. The
mortality rate was 0.8% (1/123). There was a steady decrease in AAA sac size from base-
line (5.56 ± 0.1 cm), to 6 months (5.0 ± 0.14 cm, P = .0006), to 12 months (4.65 ±
0.13 cm, P = .04), and to 24 months (4.26 ± 0.16 cm, P = .03). At 24 months, 74%
(29/39) had a decrease in sac size of 0.5 cm or more, with 28% (11/39) complete col-
lapse. Patients with initial endoleaks had the same likelihood of regression of sac size (≥
0.5 cm) when compared with the group of patients with no endoleaks at the 24-month
evaluation (64% vs 76%, P = .09). 
Conclusion: Endoluminal AAA repair resulted in a significant reduction in sac size that
continues up to 2 years. Significant shrinkage occurs as early as 6 months after place-
ment. The initial presence of endoleaks does not predict the lack of sac regression. 
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size has been included as a sign of success on the
guidelines of the advisory committee of The Society
for Vascular Surgery/International Society of
Cardiovascular Surgery, North American Chapter.7
Shrinkage and total collapse of the aneurysmal sac,
however, remain the undisputed sine qua non of
successful treatment.
Decreasing AAA sac size implies the reduction
of intra-aneurysmal pressure and may be the best
marker of a successful treatment and reduced risk of
rupture, the ultimate goal of any therapy for this
disease. Documentation of progressive aneurysmal
sac regression after device implantation is therefore
considered a significant indicator of successful treat-
ment.8,9 Although many studies have reported the
early shrinkage of aneurysmal sacs up to 1 year, few
longer term reports are available on this important
aspect of endovascular management of AAA.1,2,5,6
The goal of this study was to report the extent and
variability of sac regression over a midterm to long-
term follow-up period after the endoluminal repair of
AAA with the Ancure device at a single institution.
METHODS
We reviewed 123 patients who underwent endo-
luminal AAA repair with the Ancure device at the
University of Pittsburgh Medical Center over a 4-
year period from February 1996 to February 2000.
All endografts were deployed in the operating room
with the patient under general anesthesia by a vascu-
lar surgeon using a 12-in digital C-arm fluoroscopy
unit (Series 9600 OEC Medical Systems, Salt Lake
City, Utah). An interventional radiologist was the
first assistant on most cases. The procedural details
have been previously reported.10,11 Most patients
were part of multicenter phase II or III FDA-
approved clinical trials with around 25% implanted
after marketing of the Ancure system. Three differ-
ent configurations of the Ancure device were used:
tube, bifurcated, and aortoiliac. All protocols were
reviewed and approved by the University of
Pittsburgh Institutional Review Board and reviewed
annually. All patients in the clinical trials signed a
research informed consent.
Determination of eligibility for endoluminal repair
was based on anatomic considerations. The two main
exclusion criteria were the length of the proximal neck
under 15 mm and inadequate access through the iliac
arteries. Approximately 25% of all infrarenal AAAs
evaluated at our institution qualified for endoluminal
repair. All eligible patients underwent preoperative
spiral computed tomography (CT) of the abdomen
and pelvis with 3-mm cuts. Preprocedural aortogra-
phy was obtained routinely during the first 2 years
(phase II) and when the anatomy was unclear by CT
evaluation for the most recent cases.
Matsumura et al9 proposed that the size of the
aneurysmal sac should be considered to be the minor
diameter of the largest section of the AAA on an axial
CT. Although this method may underestimate the
true size of the AAA in certain cases, it is more repro-
ducible, and it more accurately reflects changes over
time, by preventing inaccurate sizing that results from
the tortuosity of the AAA found in most patients.
AAA size was measured preoperatively and repeated at
6-, 12-, 24-, and 36-month follow-up using the above
technique. All measurements were performed
prospectively by the senior author (M.S.M.) with a
computer-aided digital-measuring tool.
Patients in the phase II evaluation of the Ancure
graft with a documented endoleak (either at the time
of implantation with angiography or with initial post-
operative CT) were also reevaluated at 3 months.
Patients with persistent endoleaks at 6 months
underwent angiography and aggressive treatment of
their endoleaks with percutaneous coil embolization
with 0.038-in diameter coils and Tornado microcoils
(Cook, Bloomington, Ind). The technique and
results have been previously reported.12
The extent of aortic sac wall calcification was
determined at its widest diameter. The following
classification was used to determine the extent of cir-
cumferential involvement of the calcification: 0 (0%-
25%), 1 (25%-50%), 2 (50%-75%), 3 (75%-100%).
All patients were classified according to their preop-
erative CT. Because the accepted variability of the
measurements can be as high as ± 0.5 cm,13 AAA sac
shrinkage was determined to be only significant
when there was a 0.5-cm or less decrease in sac size
from the preoperative CT. Complete collapse of the
sac was defined arbitrarily to be a reduction of 3.5
cm or less. Measurements were expressed as the
mean ± SE. The Student t test, the Fisher exact test,
and χ2 analysis were used to compare the various
groups with respect to sac diameter. Statistical sig-
nificance was defined as a P value less than .05.
RESULTS
There were 119 (97%) of the 123 total patients
in the study who underwent successful implantation
of an endoluminal device. Insertion technique was
transfemoral (unilateral for tube grafts and bilateral
for bifurcated grafts) in most cases. Three patients
required transcommon iliac insertion because of dis-
eased femoral or external iliac arterial systems. The
perioperative mortality rate was 0.8% (1/123). One
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high-risk patient from the early segment of the study
died of an autopsy-proved myocardial infarction 3
days after the procedure. There were two intraoper-
ative open conversions and two failures to access.
Four patients returned to the operating room on the
same day of treatment. One patient was bleeding
around one of the proximal hooks, two patients had
an atheromatous embolus to the tibioperoneal
trunk, and one had an occlusion of one of the limbs
that required thrombectomy and stenting.
Only a limited number of late interventions were
required. None of the patients needed explantation of
the device; none had early or late sac ruptures. One
patient with a cephalad migration of the distal attach-
ment system of a tube device was treated successfully
with a new endoluminal graft. All endoleaks were suc-
cessfully treated between 8 and 16 months after initial
implantation. Ten patients died of unrelated causes:
myocardial infarction (5), cirrhosis (1), malignancy
(2), cerebrovascular accident (1), renal failure (1). 
Of the 123 patients treated with the Ancure
device, 70 had at least a 1-year follow-up visit with
a CT evaluation. They also had a mean follow-up
period of 21.5 months and were analyzed for sac
shrinkage. These patients comprised 61 men and
nine women (age, 72 ± 0.82 years). The demo-
graphics, risk factors, and ASA classification were
similar for all subgroups.
The mean preoperative AAA size was 5.56 ± 0.1
cm (range, 4.2-8.1 cm). Longer term follow-up was
available on a smaller group of patients (39 with 24-
month, 9 with 36-month, and 1 patient had a 4-year
evaluation). Of the nine patients who had a 3-year fol-
low-up, 67% had at least a 0.5-cm reduction in sac size.
The only 4-year follow-up patient had regression of sac
size from 4.8 cm (baseline) to 2.7 cm (48 months),
which was essentially the diameter of the endograft.
Overall, there was a steady decrease in AAA sac
size from baseline to 6 months (5.0 ± 0.14 cm, P =
.0006), to 12 months (4.65 ± 0.13 cm, P = .04), to
24 months (4.26 ± 0.16 cm, P = .03) (Fig 1, Table
I). At 24 months, 74% (29/39) had a decrease in sac
size of 0.5 cm or more, with 28% (11/39) complete
collapse (Fig 2, Table I). The mean sac diameter
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Table I. Changes in the minor diameter of the aneurysmal sac over a 24-month follow-up period after
endoluminal stent-graft repair of abdominal aortic aneurysms in 70 patients
Baseline (n = 70) 6 mo (n = 48) 12 mo (n = 55) 24 mo (n = 39)
Sac size (cm)* 5.56 ± 0.1 5.0 ± 0.14* 4.65 ± 0.13* 4.26 ± 0.16*
Change in sac – 0.53 ± 0.1 –0.87 ± 0.11 –1.22 ± 0.15
minor diameter (cm)
No. of patients with 21 (44%) 38 (69%) 29 (74%)
decrease (%)†
Complete 2 (4%) 6 (11%) 11 (28%)
collapse‡
*P < .05.
†Size decrease from baseline of ≥ 0.5 cm.
‡Defined as sac size reduction to ≤ 3.5 cm.
Fig 1. Minor diameter sac regression after endoluminal abdominal aortic aneurysm repair over a 24-
month follow-up period.
reduction was reduced by 0.53 ± 0.1 cm at 6 months
and 1.22 ± 0.15 cm at 36 months (Table I). There
was documented shrinkage of the sac at all intervals.
Only three patients had a significant increase in
size (> 0.5 cm) during follow-up. All of these
patients had endoleaks and were subsequently treat-
ed. Decrease in the sac size was noted in all success-
fully treated endoleaks (complete obliteration of the
communication between the sac and the native
blood artery) during the 2-year follow-up. The three
patients who had an increase in sac size had appro-
priate sac reduction 2 years after treatment (patient
1, 5.5 cm from 5.7 cm; patient 2, 3.2 cm from 5.2
cm; patient 3, 4.4 cm from 5.5 cm).
Graft configuration was primarily bifurcated
(47/70 [67%]). The tube (17/70 [24%]) and aortoil-
iac (6/70 [9%]) grafts were used in one third of cases.
Tube grafts were associated with more endoleaks
(10/17 [58%]) than the bifurcated devices (12/47
[25%]), (P = .01). No significant difference in sac
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Fig 2. A, Computed tomography of 76-year-old patient 1 month after endoluminal repair of a 6-cm
abdominal aortic aneurysm. Despite the severe calcification, the sac has decreased to 5 cm. B,
Computed tomography of same patient 13 months after endoluminal repair. Note sac has essentially
collapsed around the stent-graft and now measures 3 cm.
Table II. Effect of the type of endoluminal stent-graft used in determining the minor diameter of the
aneurysmal sac over a 24-month follow-up period
Preop 6 mo 12 mo 24 mo
Tube (n) 17 14 13 10
Size (cm) 5.1 ± 0.14 4.58 ± 0.24 4.2 ± 0.2 4 ± 0.3
No. of patients with 5 (36%) 9 (69%) 7 (70%)†
decrease (%)*
Complete 2 (14%) 2 (15%) 4 (40%)
collapse‡
Bifurcated(n) 47 30 38 25
Size (cm) 5.69 ± 0.13 5.17 ± 0.17 4.7 ± 0.17 4.3 ± 0.2
No. of patients with 15 (50%) 28 (74%) 20 (80%)†
decrease (%)*
Complete 1 (3%) 4 (11%) 4 (16%)
collapse‡
*Size decrease from preop of ≥ 0.5 cm.
†P > .05 .
‡Defined as sac size reduction to ≤ 3.5 cm.
A B
shrinkage was noted between configuration at 6
months or 1 year. At 24 months, however, more
patients with the bifurcated device had a significant
reduction in size than the tube grafts (Table II).
Twenty-four patients were determined to have a
calcification index of 0 (0%-25%). The majority of the
group (34/70, 49%) had only partial calcification: an
index of 1 (25%-50%) and 2 (50%-75%). More
patients in the 0 group had measurable decreases in
sac size at the 2-year interval than those patients with
severe calcification (index of 3, 66% vs 79%, P < .02,
Table III). However the rate of complete collapse of
the sac in both groups was similar (Table III).
Twenty-five patients were documented to have
an endoleak. The majority of these were type II, but
the exact type or origin of the endoleaks was difficult
to ascertain on the basis of CT scans. Sixteen sealed
spontaneously, and eight were treated successfully
with percutaneous coil embolization and oblitera-
tion of the endoleak. One patient with a shrinking
AAA, a persistent endoleak, and progressive heart
failure was not treated. He died of cardiac problems
at 14 months. This group of patients with an initial
endoleak had similar regression of sac size (≥ 0.5
cm) at 24 months, when compared with the group
of patients who never exhibited an endoleak (64%
and 76%, respectively; P = .09; Table IV). There was
no difference in sac shrinkage between the treated
endoleak group and the untreated endoleak group,
who spontaneously sealed (P > .05).
DISCUSSION
This study represents a prospective evaluation of
AAA sac morphology after endoluminal repair with
one of the first two FDA-approved devices to be
released for general use. It is one of the earliest
reports of AAA sac regression extended to 2 years
now that a significant number of patients treated
between 1996 and 1998 are returning for 2- and 3-
year follow-up. Shrinkage of the AAA sac has been
demonstrated to occur as early as 6 months after
implantation of the Ancure endograft with a steady
regression up to 2 years.
Malian et al,14 in one of the few reports to go
beyond 1 year of follow-up, proposed that most of
the regression of the AAA sac occurred in the first
year with minimal changes thereafter. Our data,
however, reveal a progressive reduction in the
mean size of the AAA by an additional 0.4 cm
between 12 and 24 months. A complete collapse
of the AAA is also much more likely during the
second year of follow-up when compared with the
first. In addition, a small percentage of patients
who had not yet shown a reduction in size by 12
months will show regression at the 2-year follow-
up. These results are very encouraging for long-
term efficacy of endoluminal repair of AAA.
The definition of significant reduction in size was
arbitrarily set at a minimum of 0.5 cm. This was in
keeping with the definitions used in the multicenter
phase II trials approved by the FDA. Large-scale analy-
ses of interobserver and intraobserver variability in eval-
uating AAA size from CT scans has shown that a 5-mm
threshold would represent an actual change in the
aneurysm rather than measurement error.13 The use of
the minor diameter on the axial slices also ensures the
reduction in measurement variability due to tortuosity
of the AAA and positioning of the patient.
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Table III. Effect of calcification in determining the minor diameter of the aneurysmal sac over a 24-month
follow-up period
CA class Preop 6 mo 12 mo 24 mo
CA = 3 (n) 12 9 12 9
Size (cm) 5.38 ± 0.24 5.1 ± 0.32 4.74 ± 0.3 4.4 ± 0.4
No. of patients with 4 (44%) 9 (75%) 6 (66%)†
decrease (%)*
Complete collapse‡ 0 (0%) 1 (8%) 3 (33%)
CA = 0 (n) 24 21 17 19
Size (cm) 5.62 ± 0.19 4.99 ± 0.23 4.74 ± 0.21 4.22 ± 0.21
No. of patients with 8 (38%) 12 (71%) 15 (79%)†
decrease (%)*
Complete 1 (5%) 2 (12%) 6 (32%)
collapse‡
CA 3 represents severe (75%-100%) circumferential calcification. CA 0 represents minimum (0%-25%) calcification.
*Size decrease from preop of ≥ 0.5 cm.
†P < .05.
‡Defined as sac size reduction to ≤ 3.5 cm.
Not all reports of size changes have used the same
standards. The French Vanguard trial reported a
reduction of at least 0.3 cm for 27% of the patients at
6 months.3 Despite a more rigid criterion, we noted
that 44% of the patients had at least a 0.5-cm
decrease in AAA sac diameter at 6 months. Although
the French trial reported that 75% of the patients
with a follow-up period between 12 and 24 months
had a reduction, the magnitude of the change was
not specified. Mean sac shrinkage at 1 year has been
uniform across studies using the Ancure endograft.
May et al15 reported a 0.93-cm maximal AAA sac
diameter reduction after 1 year in 30 patients similar
to the 0.87 cm in the current report. At 2 years, the
mean reduction in our study reached 1.22 cm. Other
reports only reveal slight changes in AAA sac mor-
phology during the early follow-up periods.2,6,8,16
Although the significance of endoleaks after
endoluminal AAA repair is still unknown to a large
extent, an increasing number of reports are propos-
ing that endoleaks are in fact responsible for failure
of treatment.8,15,17 It is well accepted that the pres-
ence of an endoleak has the potential to increase
AAA sac size, intramural pressure, and possibly lead
to late rupture.9,18 Therefore, we evaluated our
study group with respect to this problem. Contrary
to what is reported in the literature,8,9,15 we found
that the endoleak group had comparable sac shrink-
age especially after long-term follow-up. This result
was most likely the result of our aggressive stance to
treat all patients with persistent endoleaks with coil
embolization. Only three patients still exhibited an
endoleak at 1 year and none after 18 months. All
three of these patients eventually underwent coil
embolization and successful treatment of the
endoleak. This obviously implies that patients with
an initial endoleak can expect sac regression when
the endoleak seals spontaneously or with treatment.
The group who underwent coil embolotherapy had
outcomes similar to the spontaneously sealed group
at 2 years (Table IV). These data reveal that
embolotherapy is an important adjunct for success-
ful endoluminal AAA repair and should be available
to surgeons who perform this operation.
The calcification at the level of the aortic wall
was also investigated in our study as a possible neg-
ative etiologic factor in sac regression. The classifica-
tion scheme provided a method of quantification for
circumferential calcium deposits. Interestingly, there
were no significant differences among the groups
with respect to size, but there was a difference
between group 3 and group 0 in the number of
patients who had sac reduction of 0.5 cm or more at
the end of the 2-year follow-up period. It can be
speculated that even the heavily calcified AAA sac
may ultimately undergo remodeling when the pres-
sure and flow are redirected. Thus, calcification of
the aortic wall, though not a strong predictor of
endograft failure, should be considered a factor in
lack of sac regression if there is 75% to 100% cir-
cumferential involvement.
The concept of AAA sac regression after endolu-
minal repair appears intuitive. When the arterial
pressure is redirected through the endoluminal
device, the AAA sac should collapse around the
graft.19,20 However, this is not always the case.
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Table IV. Effect of endoleak in determining the minor diameter of the aneurysmal sac over a 24-month
follow-up period. Note that all patients with a persistent endoleaks were treated with embolotherapy at the
6-month follow-up visit.
Preop 6 mo 12 mo 24 mo
No leak (n) 45 27 38 25
Size (cm) 5.49 ± 0.12 4.89 ± 0.22 4.56 ± 0.16 4.25 ± 0.2
No. of patients with decrease (%)* 12 (44%) 27 (71%) 19 (76%)
Total leak (n) 25 21 17 14
Size (cm) 5.63 ± 0.17 5.14 ± 0.14 4.84 ± 0.22 4.23 ± 0.25
No. of patients with decrease (%)* 8 (38%) 9 (53%) 9 (64%)
SS group (n) 16 13 13 10
Size (cm) 5.64 ± 0.26 4.91 ± 0.2 4.6 ± 0.23 4.1 ± 0.28
No. of patients with decrease (%)* 6 (46%) 9 (69%)† 8 (80%)†
CE group (n) 9 8 7 7
Size (cm) 5.61 ± .07 5.59 ± .08 5.63 ± 0.38 4.68 ± 0.56
No. of patients with decrease (%)* 1 (13%) 2 (29%)† 3 (43%)†
*Size decrease from preop of ≥ 0.5 cm.
†P < .05 cm.
CE, Coil embolization; SS, spontaneous seal.
When AAAs are excluded by simple ligation and
bypass graft, leaving patent lumbar arteries and the
inferior mesenteric artery, a number of these patients
can continue to expand and even rupture.21 Another
proposed theory implicates a neointimal hyperplastic
reaction over the endograft surface, which in turn
causes a fibrotic shrinkage of the AAA sac.19 This
fibrotic process has not been confirmed clinically but
is reported to occlude small arterioles and even lum-
bar arteries, helping obliterate the sac.
In summary, our review supports the notion that
endoluminal AAA repair is very effective in reducing
the size of the AAA, a process that continues past the
first year of treatment. The threat of rupture and
continued expansion were minimal. Patients with
endoleaks after treatment behave similarly to those
who have initial complete AAA exclusion. Three of
four patients treated with the Ancure device can be
expected to have at least a 0.5-cm reduction in sac
size by 2 years with minimal or no risk of rupture. 
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Dr William J. Quinones-Baldrich (Los Angeles, Calif). I
would like to thank the Society for the opportunity to dis-
cuss this paper and congratulate Dr Rhee and his colleagues
on an excellent presentation. Decreasing the size of the
aneurysm sac after endoluminal repair is intuitively the best
evidence of an effective treatment. The series presented by
Dr Rhee today is an extremely encouraging report docu-
DISCUSSION
menting that decrease in the aneurysm sac by more than 5
mm occurs in 74% of patients treated with the Ancure
endovascular graft at 2 years. Twenty-eight percent of
patients have complete collapse defined by regression of the
aneurysm sac less than 3.5 cm. Importantly, the decrease in
the aneurysm sac appears to continue as the time of follow-
up is increased. The presence or absence of calcification in
the aneurysm wall did not appear to significantly alter the
outcome. There was no difference in the sac shrinkage
between those patients that had a treated endoleak and those
that were untreated. It’s still unclear to me after your pre-
sentation and reading the manuscript whether or not you
had any endoleaks at the end of 1 year and you may want to
clarify this issue. In a recent presentation at the Pacific Coast
Surgical Association, the Stanford group reported their expe-
rience with the AneuRx system and only about 15% to 20%
of patients had any significant decrease in the aneurysm sac
greater than 5 mm at the end of the 1-year follow-up. This
is significantly different than the 1- or 2-year data reported
today with the Ancure/EVT device. Can you explain the dif-
ference in the reported incidence of sac shrinkage between
the AneuRx and the Ancure system? Could it be related to
the particular characteristics of the devices? The authors were
not able to establish the amount of calcification in the
aneurysm wall as a significant predictor of the behavior of the
sac following endoluminal repair. They really only had nine
patients at 24 months, which is where they achieved statisti-
cal significance, and six of the nine patients actually had sac
shrinkage. They also proposed that aggressive treatment of
an endoleak was responsible for eventual sac shrinkage in
some of their patients; however, they were not able to estab-
lish the presence or absence of an endoleak as a definite pre-
dictor. In my opinion, one factor that may have significant
influence in the behavior of the aneurysm sac is the amount
of chronic thrombus already present within the aneurysm at
the time of graft implantation, which leads to my second
question. Did the authors look at the amount of chronic
thrombus within the aneurysm on the preoperative CT to
see if this had any predictive value on the actual behavior of
the sac after repair? One of the more disturbing aspects that
has been documented during follow-up of patients after
endovascular aneurysm repair is the occasional patient that
has an increase in the aneurysm sac in spite of the absence of
a demonstrable endoleak. This has led some to postulate the
concept of endotension within the aneurysm sac in spite of
what appears to be complete exclusion with the endovascu-
lar graft. Again, after listening to your presentation and read-
ing the manuscript, I am still unclear as to how many patients
had an endoleak at the one year interval. Could you please
clarify this? And this leads me to my last question. In how
many patients did you observe an increase in the aneurysm
sac and correlate this with the presence or absence of an
endoleak? The data presented here today are extremely
encouraging and support the notion that endovascular
aneurysm repair can be an effective form of treatment. We
certainly do not understand all the factors that influence the
behavior of the aneurysm sac, particularly as it relates to the
characteristics of the device itself. I am encouraged and repair
enthusiastic about the endoluminal approach for aneurysm
repair, and I congratulate the authors on an important con-
tribution and an excellent presentation.
Dr Robert Y. Rhee (Pittsburgh, Pa). Thank you Dr
Quinones-Baldrich for reviewing our paper. We, too, were
very encouraged by the results of the study. The answer to
the first question is one patient. This patient was not treat-
ed because of medical problems. Interestingly, the sac in
this patient still regressed in size in spite of the endoleak.
The remainder of the 25 patients with an endoleak were
successfully treated at the 6-month or the 1 year follow-up.
The second question regarding the possible differences
between the Ancure and AnueRx devices is difficult to
answer. One could only speculate that maybe the exoskele-
ton of the stent-graft devices may prevent significant sac
regression. The issue of the role of thrombus was investi-
gated in our study but not included in the data because it
had no significant effect in sac regression. Finally, most of
the patients with persistant endoleaks were noted to have
sacs either that changed little in size or even increased over
the 1-year follow-up period. However, all of these patients
with endoleaks after 6 months were treated and subse-
quently experienced appropriate decrease in sac size.
Dr Christopher Zarins. (Stanford, Calif). I’d like to con-
gratulate Dr Rhee on a beautiful presentation of very impor-
tant data. I rise to ask the question about outcome end
points. We frequently use endoleaks and changes in
aneurysm size as the end point of analysis, and we’re very
happy when we have no endoleak and we’re happy when the
aneurysm decreases in size. And you’ve shown that you can
achieve both of these. We have looked at our data at Stanford
and looked at more than 100 patients over a year out, and
we found that the rate of decrease in aneurysm size pretty
much equals the reported rate of increase in aneurysm size
in the natural history of study of aneurysms. But the inter-
esting thing was that some, just as in aneurysm enlargement,
enlarge very rapidly and rupture, and we also found that
some aneurysms decrease very greatly in size. Now your
paper suggested that that is a favorable and a good thing.
But what we have found is that in a couple of patients who
have late-onset acute endoleaks, even though the aneurysm
has collapsed like a balloon, once you repressurize it, it reex-
pands like a balloon and perhaps has an increased chance of
rupture. In the large AneuRx trial of over 1000 patients
there was one patient who decreased in size from 9 cm to 6
cm and then ruptured. Never had an endoleak. So all of the
favorable outcome analyses, no endoleak, and decreasing
aneurysm size do not guarantee that you’ll have a long-term
outcome and no aneurysm rupture, so I think that in con-
sidering these end points that is really not the purpose of
treatment (that is to prevent aneurysm rupture). Do we have
a sense of security that we have indeed cured the patient if
we have a decreasing-size aneurysm and no endoleak?
Dr Rhee. Thank you Dr Zarins for your thoughts. We,
too, feel that regression of the sac is only one of the indi-
cators of success for endovascular AAA treatment.
However, we also feel that it is the most important objec-
tive evidence that we have to date that this new method of
treatment is actually preventing AAA expansion and possi-
bly rupture. Obviously, longer term follow-up is needed
before these data can be put in perspective.
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